Friday, 16 October 2026European Markets

ADC SIIC Stock Jumps By 29% In The Last 10 Sessions

Loading stream...

adc siic, a real estate investment firm, experienced a significant rise in its stock performance recently. over a span of 10 sessions, its shares escalated by 29.63% to a value of eur0.07. this came as a recovery from successive losses and was accompanied by a subsequent rise in the cac 40 index, which saw an increase of 1.02% to stand at eur7,343.96.

stock performance overview

the shares of adc siic have exhibited a swing in their performance, where they have overrun their 52-week low of eur0.05 and yet have not hit their 52-week high of eur0.08. this swing in performance mirrors the financial health of the company in recent years.

financial performance

adc siic demonstrated a substantial year-over-year quarterly revenue growth. it marked an increase of 351.3%, reaching a volume of 1.01m for the trailing twelve months. despite such an impressive revenue upswing, the company unfortunately couldn't utilize it towards yielding profits, resulting in negative earnings per share (eps) of eur-0.01 and an equity return rate of -1.87%.

trading volume and investor activity

adc siic, even with its recent surge in stock price, witnessed a trading volume of only 6,000 which is much below its average volume of 9,222. this suggests that investor activity is rather inactive, as not many are engaging in trading this stock despite its shift in momentum.

stock's future prospects

adc siic's stock value currently leads beyond its 50-day and 200-day moving averages of eur0.07. nevertheless, its future prospects are shadowed by negative eps, a sluggish trading volume, and an absence of profitability. as a result, prospective investors must practice extreme caution before considering this stock because of the inherent volatility and financial risk associated with it.

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com